Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26669205 | 0.83 | CKS1B (0.55) | GPR119ACHEMAP4K4CKS1BSKP1 | |
| SCHEMBL22391741 | 0.82 | GPR119 (0.50) | GPR119ACHEMAP4K4CKS1BSKP1 | |
| SCHEMBL6784438 | 0.81 | GPR119 (0.46) | GPR119ACHEMAP4K4CKS1BSKP1 | |
| SCHEMBL26669216 | 0.81 | CKS1B (0.53) | GPR119ACHEMAP4K4CKS1BSKP1 | |
| SCHEMBL15106095 | 0.81 | GPR119 (0.55) | GPR119ACHEMAP4K4CKS1BSKP1 | |
| SCHEMBL3486907 | 0.80 | GPR119 (0.63) | GPR119ACHECKS1BSKP1SKP2 | |
| SCHEMBL31453948 | 0.79 | GPR119 (0.56) | GPR119ACHEMAP4K4CKS1BSKP1 | |
| SCHEMBL5884056 | 0.78 | CKS1B (0.46) | GPR119ACHEMAP4K4CKS1BSKP1 | |
| SCHEMBL16333334 | 0.77 | HRH3 (0.56) | GPR119ACHEMAP4K4CKS1BSKP1 | |
| SCHEMBL905995 | 0.76 | HRH3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995159-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-03-10 | — | — | US | disclosed |
| US-20050032809-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-02-10 | — | — | US | disclosed |
| US-6825198-B2 | FOR THERAPY OF SEXUAL DISORDER | PFIZER INC | 2004-11-30 | — | — | US | disclosed |
| EP-1401819-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-06-05 | — | — | US | disclosed |
| WO-2003000663-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032809-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | GPR119 54/4885ACHE 610/4885MAP4K4 3156/4885 |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | GPR119 61/4885ACHE 638/4885MAP4K4 3305/4885 |
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | GPR119 54/4885ACHE 610/4885MAP4K4 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.